LTS Acquires Sorrel Wearable Injection Device Business

LTS Lohmann Therapie-Systeme AG, a leading pharmaceutical technology company, has completed its acquisition of the Sorrel wearable injection device business from Eitan Medical Ltd.

The acquisition is a crucial step in LTS’ strategy to broaden its portfolio of drug delivery platforms and support pharma partners in the field of large molecules and biologics. Sorrel will become part of the worldwide network of LTS and operate as a new LTS division named LTS Device Technologies.

Bas van Buijtenen, CEO of LTS, commented: “The acquisition of our new Device Technologies platform catapults LTS into the world of drug delivery for large molecules, and fulfils our mission to bring empowering solutions to patients that rely on cumbersome and expensive therapies requiring in-clinic administration or multiple injections.”

Terms of the transaction were not disclosed.